Two-year oral IL-23 data, GLP-1 biomarker findings, and a nonsurgical option for superficial basal cell carcinoma headline the sessions covered in Las Vegas.
|Articles|May 6, 2023
POLL: How Do You Enhance the Patient Experience?
Author(s)Lauren Buchanan, MA, Managing Editor
One ACMS session focused on creating a memorable experience for patients with office space, online presence, and practice management to attract and retain great patients and staff.
Advertisement
This question was a conversation starter during the session "Growing a Successful Mohs Practice: SEO, Social Media, etc." at the
Pearls from this session will be posted throughout the weekend. Don't miss a moment of ACMS Coverage! Subscribe to
How do you enhance the patient experience?
Advertisement
Related to this article
Prospective data suggest DecisionDx-Melanoma may help refine SLNB decisions and identify recurrence risk beyond conventional staging.
Phase 3 data show intismeran plus pembrolizumab reduced recurrence or death risk by 42% in patients with resected stage IIB-IV melanoma.
The 3rd annual meeting in Atlanta gives dermatology NPs and PAs 4 case-based breakout sessions and a general education session in a focused, small-group setting.
Shannon Trotter, DO, moderated a Dermatology Times Case-Based Roundtable event on how pharmacokinetics, adverse event timing, and trial response criteria should shape hedgehog pathway inhibitor selection in advanced BCC.
SPD 2026 highlighted advances in pediatric dermatology spanning textured hair care, vitiligo, vascular anomalies, mental health, genetics, and collaborative care.
A retrospective claims analysis of 2897 matched pairs found hazard ratios of 0.48 to 0.67 for new atopic disease with dupilumab vs systemic corticosteroids in children.
Falk G. Bechara, MD, discusses long-term tunnel control, structural damage, and the evolving role of biologics and surgery in HS care.
Advertisement
Advertisement
Trending on Dermatology Times
1
ORKA-001 Achieves 61% Complete Skin Clearance in Psoriasis
2
How Approvals, Setbacks, and a Crowded Pipeline Are Reshaping the AD Treatment Landscape
3
FDA Revises TB Evaluation Guidance for SKYRIZI
4
Avoiding Common Mistakes When Escalating Therapy in Psoriasis
5